AA
JAZZ icon

Altman Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Altman Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-10,091
Closed -$1.52M – 84
2018
Q1 		$1.52M Buy
10,091
+141
+1% +$20.7K 1.46% 41
2017
Q4 		$1.34M Buy
+9,950
New +$1.38M 1.17% 48

Other funds holding JAZZ

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Altman Advisors's JAZZ Position: Q2 2018 in Review

Altman Advisors sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2018, closing a stake of 10,091 shares — an estimated $1.52M sold.

Altman Advisors first reported a position in JAZZ in Q4 2017 and held it in 2 quarters. The position peaked at $1.52M in Q1 2018. 376 funds tracked by Wall St. Rank hold JAZZ as of Q2 2018.

  • Altman Advisors reported no remaining Jazz Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Altman Advisors sold 10,091 Jazz Pharmaceuticals shares in Q2 2018, an estimated $1.52M.
  • Altman Advisors first reported a position in Jazz Pharmaceuticals in Q4 2017 and held it in 2 quarters.
  • Altman Advisors's Jazz Pharmaceuticals position peaked at $1.52M in Q1 2018.
  • 376 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2018.

Based on Altman Advisors's 13F filing for Q2 2018, filed 2 Aug 2018.